479 related articles for article (PubMed ID: 28726132)
1. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
[TBL] [Abstract][Full Text] [Related]
3. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D; Barker D; Sharma R; Brunetto AT; Yap TA; Taegtmeyer AB; Barriuso J; Medani H; Degenhardt YY; Allred AJ; Smith DA; Murray SC; Lampkin TA; Dar MM; Wilson R; de Bono JS; Blagden SP
Clin Cancer Res; 2011 May; 17(10):3420-30. PubMed ID: 21459796
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
[TBL] [Abstract][Full Text] [Related]
6. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A
Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827
[TBL] [Abstract][Full Text] [Related]
11. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Jimeno A; Li J; Messersmith WA; Laheru D; Rudek MA; Maniar M; Hidalgo M; Baker SD; Donehower RC
J Clin Oncol; 2008 Dec; 26(34):5504-10. PubMed ID: 18955447
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
17. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
[TBL] [Abstract][Full Text] [Related]
18. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
20. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
